What the data shows
The emergence of the Cicada COVID variant BA.3.2 raises a pressing question: How does this new variant impact our current understanding of immunity and public health? The answer is that BA.3.2, with its significant mutations, poses a challenge to existing vaccine efficacy, although it is not associated with more severe disease.
BA.3.2, also known as ‘Cicada’, is characterized by an astonishing 70-75 mutations in its spike protein, which may allow it to evade immunity from both vaccines and previous infections. First identified in South Africa in November 2024, this variant has since made its way to the United States, where it was detected in June 2025 in a traveler returning from the Netherlands. As of February 11, 2026, BA.3.2 has been reported in at least 25 states across the U.S., indicating a rapid spread.
Symptoms associated with BA.3.2 include cough, fever, sore throat, congestion, shortness of breath, loss of smell or taste, fatigue, headache, and gastrointestinal issues like diarrhea or vomiting. Despite these symptoms, health experts, including Dr. Robert H. Hopkins Jr., have noted that there is no evidence suggesting that Cicada causes more severe illness compared to other circulating variants. This is a crucial point, as it suggests that while the variant may be more transmissible, it does not necessarily lead to increased hospitalizations.
Vaccination remains a key defense against severe outcomes from BA.3.2. As Andrew Pekosz, a prominent virologist, stated, “Vaccination is still going to help limit cases.” The function of the vaccine, as emphasized by Dr. Schaffner, is primarily to keep individuals out of the hospital, which remains a critical goal in managing the pandemic.
Despite the reassuring news regarding disease severity, the variant’s high mutation rate raises concerns about its ability to evade immune responses. Pekosz further noted, “It has a lot of mutations that may cause it to look different to your immune system.” This underscores the importance of ongoing surveillance and research to understand the variant’s implications fully.
Details remain unconfirmed regarding the exact reasons for the resurgence of BA.3.2. The variant emerged over a year ago and began to gain traction last fall, but the factors contributing to its spread remain unclear. Additionally, the long-term impact of BA.3.2 on COVID-19 infection rates is uncertain, leaving public health officials and researchers on alert.
As of now, BA.3.2 accounts for approximately 30% of COVID-19 infections in some Eastern European countries, highlighting its potential for widespread transmission. In the U.S., it has been detected in 132 sites through wastewater samples, a method that has become increasingly important in tracking the spread of variants.
In summary, while the Cicada variant BA.3.2 presents challenges due to its mutations, the current understanding suggests that vaccines continue to provide protection against severe disease. Ongoing research and vigilance will be essential as we navigate the evolving landscape of COVID-19 variants.
